Date: 2011-11-02
Type of information: Commercialisation agreement
Compound: Mitoxis® functional metabolomics platform
Company: BioQuanta (France) Gentronix (UK)
Therapeutic area:
Type agreement: distribution
commercialisation
Action mechanism: Mitoxis® has been developed on highly automated analyzers used in clinical biology, and is different from systems based on microplate technology, thus delivers results with the unparalleled precision of clinical diagnostics. The speed and accuracy of the Mitoxis® approach allows the simultaneous analysis of many parameters (> 30) on the same reduced sample volume of < 5µl, with limited or no sample preparation. With an overall CV < 4%, inter-sample variability is lowered, leading to increased confidence in the results and a better understanding of inter-dependencies between parameters. Mitoxis® provides unmatched results to evaluate side effects of exogenous molecules (therapeutic, cosmetic or industrial) on the main transversal metabolic pathways of the cell. The platform was developed to meet the same performance criteria of standard operating procedures in place for clinical biology and is the result of expertise gained from performing millions of tests per year routinely in a French public hospital.
Disease:
Details: Gentronix Limited, the specialist genotoxicity assay provider and BioQuanta SA, a French company engaged in the implementation of predictive and personalized medicine have signed a commercial agreement covering the commercialization of the Mitoxis® functional metabolomics platform from BioQuanta.
Under the terms of the agreement Gentronix will become a worldwide distributor of Mitoxis® services giving customers access to over 70 discrete assays central to a deeper understanding of cell health. This comprehensive range of assays covers key functional metabolisms important for the early detection of toxicity liabilities, including the electron-transport chain, oxidative stress, cellular energy status, inflammation and cell death.
Financial terms:
Latest news:
